



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/070,161	03/04/2002	Yuichi Oku	MIT-C205 9188	
30132 7.	590 03/17/2006		EXAMINER	
GEORGE A. LOUD 625 SLATERS LANE			COUNTS, GARY W	
FOURTH FLO			ART UNIT PAPER NUMBER	
ALEXANDRIA, VA 22314			1641	
			DATE MAILED: 03/17/2000	5 .

Please find below and/or attached an Office communication concerning this application or proceeding.

h	Application No.	Applicant(s)	
Advisory Action	10/070,161	OKU ET AL.	
Before the Filing of an Appeal Brief	Examiner	Art Unit	
	Gary W. Counts	1641	
The MAILING DATE of this communication appe	ars on the cover sheet with the o	orrespondence add	lress
THE REPLY FILED <u>06 March 2006</u> FAILS TO PLACE THIS AF		•	
1. ☐ The reply was filed after a final rejection, but prior to or or			nandonment of
this application, applicant must timely file one of the follo places the application in condition for allowance; (2) a No (3) a Request for Continued Examination (RCE) in complete following time periods:	wing replies: (1) an amendment, a otice of Appeal (with appeal fee) in liance with 37 CFR 1.114. The repl	ffidavit, or other evidence with 37 (ence, which CFR 41.31; or
a) \square The period for reply expires $\underline{5}$ months from the mailing date of			
b) The period for reply expires on: (1) the mailing date of this Adviewent, however, will the statutory period for reply expire later that	an SIX MONTHS from the mailing date o	f the final rejection.	
Examiner Note: If box 1 is checked, check either box (a) or (b). MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f)		RST REPLY WAS FILE	D WITHIN TWO
Extensions of time may be obtained under 37 CFR 1.136(a). The date on) and the appropriate ext	ension fee have
been filed is the date for purposes of determining the period of extension a CFR 1.17(a) is calculated from: (1) the expiration date of the shortened sta above, if checked. Any reply received by the Office later than three months earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	atutory period for reply originally set in the	final Office action; or (2)	as set forth in (b)
2. The Notice of Appeal was filed on A brief in com	pliance with 37 CFR 41.37 must be	e filed within two mor	nths of the date
of filing the Notice of Appeal (37 CFR 41.37(a)), or any e	xtension thereof (37 CFR 41.37(e)), to avoid dismissal	of the appeal.
Since a Notice of Appeal has been filed, any reply must b	pe filed within the time period set for	orth in 37 CFR 41.37	(a).
AMENDMENTS			
 The proposed amendment(s) filed after a final rejection, They raise new issues that would require further co 			because
(b) They raise the issue of new matter (see NOTE belo	•	∩ ⊏ below),	
(c) They are not deemed to place the application in bet appeal; and/or		educing or simplifying	g the issues for
(d) They present additional claims without canceling a	corresponding number of finally re	ejected claims.	
NOTE: (See 37 CFR 1.116 and 41.33(a)).			
4. The amendments are not in compliance with 37 CFR 1.1		ompliant Amendmen	t (PTOL-324).
5. Applicant's reply has overcome the following rejection(s	· ——		
 Newly proposed or amended claim(s) would be a the non-allowable claim(s). 			
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows:	☐ will not be entered, or b) ☒ wivided below or appended.	ill be entered and an	explanation of
Claim(s) allowed: <i>NONE</i> . Claim(s) objected to: <i>NONE</i> .			
Claim(s) objected to: <u>NONE</u> . Claim(s) rejected: <u>1,4-7,9-23 and 26-28</u> .			
Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
8. The affidavit or other evidence filed after a final action, be because applicant failed to provide a showing of good an and was not earlier presented. See 37 CFR 1.116(e).			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to of showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rejections under appe	al and/or appellant fa	ails to provide a
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER			
The request for reconsideration has been considered bu See continuation.	ut does NOT place the application	in condition for allowa	ance because:
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08 or PTO-1449) Paper	No(s).	
13. Other:	(162	0

U.S. Patent and Trademark Office PTOL-303 (Rev. 7-05) BAO-THUY L. NGUYEN PRIMARY EXAMINER Art Unit: 1641

Attachment to Advisory Action

Continuation of 11 NOTE:

Applicant argues that the Examiner actually describes two significantly different assays, both of which are significantly different from that shown in Fig. 5. Applicant describes the assays of Niemeyer et al and appears to be arguing that the two receptors I and II are not used in the same assay. Applicant directs Examiner's attention to Attachments A-C to show different assays. This is not found persuasive because the Applicant is not on point with the argument. The instantly recited claims are directed to a kit comprising reagents to be used in assays. The currently recited claims are not drawn toward assay methods or assay steps. Even if Niemeyer et al is teaching different assays, Niemeyer et al clearly teaches receptors I and II as claimed and teaches packaging reagents into a kit. Niemeyer et al disclose a bioconjugate (receptor II) comprising DNA-STV hybrids (DNA (B3)- STV (strepavidin, R2) bound to a biotinylated (B2) antibody (L2) (p. 14, para. 0127, lines 9-10). Niemeyer et al disclose that the solid phase oligonucleotides (R3) is capable of binding to the DNA (B3) of the DNA-STV hybrid. Niemeyer et al disclose that the bioconjugate binds to a target analyte such as an antibody (p. 14, para. 0127, lines 11-13). Niemeyer et al disclose another conjugate (receptor I). Niemeyer et al disclose that this conjugated compound comprises biotinylated (B1) antibody (L1) combined with streptavidin (R1) coupled to nucleic acid (M) (p. 8, para. 0079, lines 43-60). Niemeyer et al disclose that the bioconjugates can be packaged into a kit (p. 2, para. 0017).

Application/Control Number: 10/070,161

Art Unit: 1641

Page 3

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gary W. Counts whose telephone number is (571) 2720817. The examiner can normally be reached on M-F 8:00 - 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on (571) 272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Gary Counts

Examiner

Art Unit 1641

March 10, 2006